Editorial
doi: 10.1200/JCO.2007.11.5113.
Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
- PMID: 17634476
- DOI: 10.1200/JCO.2007.11.5113
Item in Clipboard
Editorial
Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
J Clin Oncol.
.
No abstract available
Comment on
-
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.J Clin Oncol. 2007 Jul 20;25(21):3045-54. doi: 10.1200/JCO.2006.07.2066. J Clin Oncol. 2007. PMID: 17634482 Clinical Trial.
Similar articles
-
Hypertension and proteinuria: a class-effect of antiangiogenic therapies.Anticancer Drugs. 2009 Jan;20(1):81-2. doi: 10.1097/CAD.0b013e3283161012. Anticancer Drugs. 2009. PMID: 19343005
-
Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.Expert Rev Anticancer Ther. 2009 Oct;9(10):1413-6. doi: 10.1586/era.09.116. Expert Rev Anticancer Ther. 2009. PMID: 19828000 No abstract available.
-
Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.Cancer Treat Rev. 2011 Aug;37(5):344-52. doi: 10.1016/j.ctrv.2011.02.002. Epub 2011 Mar 23. Cancer Treat Rev. 2011. PMID: 21435792 Review.
-
Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.Expert Opin Drug Metab Toxicol. 2012 Mar;8(3):283-93. doi: 10.1517/17425255.2012.656845. Epub 2012 Jan 30. Expert Opin Drug Metab Toxicol. 2012. PMID: 22283844 Review.
-
Response to anti-angiogenesis: an ever changing feature.Breast. 2011 Oct;20 Suppl 3:S61-2. doi: 10.1016/S0960-9776(11)70296-X. Breast. 2011. PMID: 22015295 Review.
Cited by
-
Nasal septum perforation and bevacizumab.Med Oncol. 2011 Mar;28(1):89-93. doi: 10.1007/s12032-010-9464-9. Epub 2010 Mar 6. Med Oncol. 2011. PMID: 20213219
-
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.J Clin Oncol. 2010 Feb 20;28(6):949-54. doi: 10.1200/JCO.2009.25.4482. Epub 2010 Jan 19. J Clin Oncol. 2010. PMID: 20085937 Free PMC article. Clinical Trial.
-
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.J Natl Cancer Inst. 2011 May 4;103(9):763-73. doi: 10.1093/jnci/djr128. Epub 2011 Apr 28. J Natl Cancer Inst. 2011. PMID: 21527770 Free PMC article.
-
Targeting prion-like protein doppel selectively suppresses tumor angiogenesis.J Clin Invest. 2016 Apr 1;126(4):1251-66. doi: 10.1172/JCI83427. Epub 2016 Mar 7. J Clin Invest. 2016. PMID: 26950422 Free PMC article.
-
Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma.Expert Opin Investig Drugs. 2009 Oct;18(10):1549-57. doi: 10.1517/13543780903183528. Expert Opin Investig Drugs. 2009. PMID: 19671039 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
